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A number of [PSI+]-no-more (PNM) mutations, eliminating [PSI+] prion, were previously
described in SUP35. In this study, we designed and analyzed a new PNM mutation
based on the parallel in-register β-structure of Sup35 prion fibrils suggested by the
known experimental data. In such an arrangement, substitution of non-charged residues
by charged ones may destabilize the fibril structure. We introduced Q33K/A34K amino
acid substitutions into the Sup35 protein, corresponding allele was called sup35-M0.
The mutagenized residues were chosen based on ArchCandy in silico prediction of high
inhibitory effect on the amyloidogenic potential of Sup35. The experiments confirmed that
Sup35-M0 leads to the elimination of [PSI+] with high efficiency. Our data suggested that
the elimination of the [PSI+] prion is associated with the decreased aggregation properties
of the protein. The new mutation can induce the prion with very low efficiency and is able
to propagate only weak [PSI+] prion variants. We also showed that Sup35-M0 protein
co-aggregates with the wild-type Sup35 in vivo. Moreover, our data confirmed the utility
of the strategy of substitution of non-charged residues by charged ones to design new
mutations to inhibit a prion formation.
Keywords: [PSI+], amyloid, ArchCandy, prion, Saccharomyces cerevisiae, SUP35 mutation,
superpleated-β-structure
1. INTRODUCTION
Prions are self-propagating and transmissible protein isoforms that cause fatal neurodegenerative
disease in humans or heritable traits in lower eukaryotes. The most known hallmark of almost all
prions is a formation of amyloid aggregates (Liebman and Chernoff, 2012). These aggregates have
a set of specific properties, such as resistance to detergents and proteases, interaction with dyes
Thioflavin T and S, birefringence when stained with the Congo Red dye, and cross-β-structure
(Baxa et al., 2006). The first discovered prion, PrPSc (“prion protein” scrapie), causes severe
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infectious neurodegenerative diseases in mammals (Prusiner,
2013). Discovery of prions in lower eukaryotes (Wickner, 1994)
revealed that this phenomenon is widespread and based on
common mechanisms. Thus, unicellular organisms such as yeast
can be used for investigation of prionization and the data
obtained can be extrapolated tomammalian prions (Liebman and
Chernoff, 2012).
One of the best-studied prions to date is [PSI+], an isoform
of Sup35 protein (Cox, 1965; Wickner, 1994; Wickner et al.,
1995), which is a eukaryotic release factor 3 (Stansfield et al.,
1995; Zhouravleva et al., 1995). This protein is divided into
three domains (N, M, and C) (Kushnirov et al., 1988).
The C-terminal part of Sup35 contains four GTP binding
sites (Stansfield et al., 1995; Zhouravleva et al., 1995) and
it is essential for the cell viability and termination of
translation (Ter-Avanesyan et al., 1993). N-domain is required
for [PSI+] maintenance (Ter-Avanesyan et al., 1994) and
formation of stress-inducible condensates (Franzmann et al.,
2018). N-domain consists of two parts — the Q/N rich
segment (1–39 aa) and the oligopeptide repeats region (OR),
containing one incomplete and five complete repeats (40–112
aa) (Kushnirov et al., 1988). The charged M-domain represents
an unfolded linker that also affects [PSI+] prion maintenance
(Liu et al., 2002; Helsen and Glover, 2012).
Cells bearing [PSI+] prion have a reduced amount of
monomeric Sup35 protein, that increases the frequency of the
read-through of premature stop codons (Liebman and Chernoff,
2012). Nonsense mutation ade1-14, which lead to the synthesis
of a truncated non-functional Ade1 protein and to the inability
of cells to synthesize adenine, is often used to test for the
nonsense suppression caused by the prion. The accumulation
of the adenine biosynthesis intermediate results in the red color
of colonies growing on the 1/4 YEPD medium. The appearance
of [PSI+] prion leads to the suppression of ade1-14 nonsense
mutation and the formation of full-length Ade1. Phenotypically
it can be detected by growth on media lacking adenine and
the white colony color. This manifestation can vary depending
on the structure of Sup35 aggregates (prion variant), templated
upon prion propagation. The term “variant” is used hereafter for
different prion variants, and “strain” — only for yeast strains.
Cells bearing weak variants of the [PSI+] prion demonstrate weak
growth on adenineless media, i.e., weak nonsense suppression,
while the strong [PSI+] variants lead to almost complete masking
of the ade1-14mutant phenotype (Liebman and Chernoff, 2012).
Different approaches may be used for investigation of Sup35
aggregates in [PSI+] cells. They can be decorated by transiently
overproduced Sup35NM-GFP and visualized with fluorescence
microscopy (Osherovich et al., 2004). Sup35 aggregates can also
be directly analyzed with biochemical approaches: differential
centrifugation, SDD-AGE (Kryndushkin et al., 2003) or
modifications of SDS-PAGE (Kushnirov et al., 2006).
Oligopeptide repeats in the Sup35 N-domain significantly
affect [PSI+] prion maintenance. At least two first ORs are
essential for the prion propagation (Liu and Lindquist, 1999;
Osherovich et al., 2004; Shkundina et al., 2006). At the same
time OR expansion leads to increased fragmentation of Sup35
aggregates, while a decrease in the number of repeats has an
opposite effect (Langlois et al., 2016). Previously, using the T-
REKS algorithm (Jorda and Kajava, 2009), we identified an
additional OR in the Sup35 N-domain, located from 28 to 40
amino acid residues (Bondarev et al., 2013). The mutation within
this OR, named sup35-M0, was designed based on the model
of a superpleated-β-structure, proposed for Sup35 aggregates
(Kajava et al., 2004). According to this model, charged amino acid
residues located inside the fibril, can destabilize this structure,
due to the electrostatic repulsion. In this work, we investigated
the effect of this mutation on the prion propagation and
properties of Sup35 aggregates.
2. MATERIALS AND METHODS
2.1. Strains, Media, and Growth Condition
Saccharomyces cerevisiae strain 7A-D832 [psi–] and its isogenic
[PSI+] derivative 10-7A-D832 (Bondarev et al., 2013) were used
in this study unless otherwise specified. Both strains contain
the sup35::TRP1 knockout on the chromosome, compensated
by plasmid(s) bearing the SUP35 gene. For the experiments
with protein transformation, the [psi–] [pin–] strain 2-OT56
(Matveenko et al., 2016) was used.
Yeast strain 12-D1682, used for the induction of new
[PSI+] variants, was constructed as follows. Strain GT671 was
transformed by pRSU2 plasmid, carrying the URA3 marker.
Transformant with the Ura+Leu– phenotype was selected and
designated as U-GT671. Yeast strain GT159 (Chernoff et al.,
1999) was transformed by the pRSU1 plasmid (Volkov et al.,
2002), carrying LEU2 marker, and mated with the U-GT671
strain. Diploids were selected on SC-Ura-Leu media. Then
random ascospore isolates were obtained, and MATa Ura–Leu+
segregant was selected and named 12-D1682 (Table 1). This
strain was transformed with a pRS316CUP-NM-GFP plasmid
for overproduction of Sup35NM-GFP. The prion induction was
performed as described below and seven prion variants were
isolated. Clones that lost pRS316CUP-NM-GFP were selected
after several passages on YEPD.
Yeast cultures were maintained on the YEPD (yeast
extract/peptone/dextrose medium) or synthetic complete
minimal medium (SC) (Kaiser et al., 1994). Solid media were
prepared with the addition of agar (2%). SC media with 5’-FOA
(1 mg/ml) was used for counter-selection of plasmids bearing
URA3 (Kaiser et al., 1994). Nonsense suppression in [PSI+]
cells was detected by the ability to grow on the SC medium
lacking adenine (SC-Ade) or by the colony color on 1/4 YEPD
(Eaglestone et al., 2000). Yeast cells were grown at 30◦C.
2.2. Plasmids
Plasmids bearing the new sup35 mutation were constructed
by site-directed mutagenesis. We amplified the vector using
highly processive DNA polymerase (AccuPrime Pfx, Invitrogen)
(the primer sequences are available upon request). The vectors
pRSU1 (Volkov et al., 2002), pRSU2 (Volkov et al., 2002),
pRS316CUP-NM-GFP (Serio et al., 1999), pRS315CUP-NM-GFP
and pET-20b-SUP35NM-His6 (Allen et al., 2005) were used
as templates. Next, the PCR mixture was treated with DpnI
(Thermo Scientific) to remove the template DNA. Then, this
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TABLE 1 | Strains of S. cerevisiae used in this study.
Strain Genotype References
7A-D832 MATα ade1-14(UGA) his7-1(UAA) leu2 lys2-739 trp1 ura3 sup35::TRP1 [pYCH-U2] [psi–] [PIN+] Bondarev et al., 2013
10-7A-D832 MATα ade1-14(UGA) his7-1(UAA) leu2 lys2-739 trp1 ura3 sup35::TRP1 [pYCH-U2] [PSI+] [PIN+] Bondarev et al., 2013
2-OT56 MATa ade1-14(UGA) trp1-289(UAG) ura3-52 his3-1200 leu2-3,112 [psi–] [pin–] Matveenko et al., 2016
GT159 MATa ade1-14(UGA) trp1-289(UAG) his3 lys2 ura3-52 leu2- 3,112 [psi–] [PIN+] Chernoff et al., 1999
GT671 MATα ade1-14(UGA) trp1-289(UAG) his3 lys2 ura3-52 leu2- 3,112 sup35::HIS3MX [CEN LEU2 SUP35] [psi–] [pin–] Gift from Y.O. Chernoff
U-GT671 MATα ade1-14(UGA) trp1-289(UAG) his3 lys2 ura3-52 leu2- 3,112 sup35::HIS3MX [pRSU2] [psi–] [pin–] This study
12-D1682 MATa ade1-14(UGA) trp1-289(UAG) his3 lys2 ura3-52 leu2- 3,112 sup35::HIS3MX [pRSU1] [psi–] [PIN+] This study
74-D694 MATa ade1-14(UGA) trp1-289(UAG) ura3-52 his3-1200 leu2- 3,112 [psi–] [PIN+] Derkatch et al., 1997
P-74-D694 MATa ade1-14(UGA) trp1-289(UAG) ura3-52 his3-1200 leu2- 3,112 [PSI+] [PIN+] Drozdova et al., 2016
solution was used for transformation of E. coli competent cells.
All mutations were verified by sequencing. To construct the
pRS315CUP-NM-GFP plasmid, we ligated the region with the
CUP1 promoter, Sup35NM and GFP from pRS316CUP-NM-
GFP (Serio et al., 1999) into the polylinker site of the pRS315
plasmid (Sikorski and Hieter, 1989). The region of interest
in pRS316CUP-NM-GFP and the polylinker site were digested
by XhoI and SacI enzymes. Sticky-end ligation was performed
with T4 DNA-ligase according to Thermo Scientific protocol.
pRS315CG was obtained analogously from pRS316CG (Serio
et al., 1999) and pRS315. pR16CUP-NM-yTagRFP-T plasmid was
obtained by insertion of the XhoI-XhoI fragment from pCUP-
NM-His6 (Kiktev et al., 2015) in place of the XhoI-SalI fragment
of pR16CUP-SFP1C-yTagRFP-T which in turn resulted from
the substitution of the PstI-PstI fragment in pR16CUP-SFP1-
Cerulean (Matveenko et al., 2016) for the PstI-PstI fragment from
pIM35 (Malcova et al., 2016). TagRFP-T is a TagRFP derivative
containing one additional substitution (Shaner et al., 2008). All
the plasmids are listed in Table 2.
2.3. Genetic and Microbiological
Procedures
Standard microbiological approaches were used for all
manipulations with yeast and bacterial colonies (Sambrook
and Fritsch, 1989). Yeast protein transformation was performed
as described previously (Tanaka and Weissman, 2006). Direct
plasmid shuffle (from wild-type to mutant allele) was performed
as follows: the [PSI+] sup35::TRP1 strain with the SUP35 gene on
a URA3 plasmid was transformed with LEU2 plasmids bearing
the wild-type or mutant SUP35 alleles. Transformants, selected
on SC medium lacking uracil and leucine (SC-Ura-Leu), were
tested for suppression of the ade1-14 mutation to determine
the presence of [PSI+]. These transformants were replica plated
on media with 5′-FOA for counter-selection of the plasmid
with SUP35, and then on the SC-Leu and SC-Ura media to
prove the loss of the plasmid. The suppressor phenotype of the
obtained strains was analyzed on SC-Ade or 1/4 YEPD. Reverse
plasmid shuffle (from mutant allele to wild-type) was performed
as follows: the strains after direct shuffle were transformed
with plasmids bearing the wild-type allele. Transformants were
selected on SC-Ura-Leu medium and then streaked out on YEPD
media to allow spontaneous plasmid loss. Colonies were replica
TABLE 2 | Plasmids used in this study.
Plasmid Description References
pRSU1 LEU2, ampR, PSUP35, SUP35 Volkov et al., 2002
pRSU1-sup35-M0 LEU2, ampR, PSUP35,
sup35-M0
This study
pRSU2 URA3, ampR, PSUP35,
SUP35
Volkov et al., 2002
pRSU2-sup35-M0 URA3, ampR, PSUP35,
SUP35
This study
pRS316CUP-NM-GFP URA3, ampR, PCUP1,
SUP35NM-GFP
Serio et al., 1999
pRS316CUP-NM-M0-GFP URA3, ampR, PCUP1,
SUP35NM-M0-GFP
This study
pET-20b-SUP35NM-His6 -, ampR, T7, SUP35-NM-His6 Allen et al., 2005
pET-20b-SUP35NM-M0-His6 -, ampR, T7,
SUP35-NM-M0-His6
This study
pRS315CUP-NM-GFP LEU2, ampR, PCUP1,
SUP35NM-GFP
This study
pRS315CUP-NM-M0-GFP LEU2, ampR, PCUP1,
SUP35NM-M0-GFP
This study
pRS315 LEU2, ampR Sikorski and
Hieter, 1989
pRS315CG LEU2, ampR, PCUP1, GFP This study
pR16CUP-NM-yTagRFP-T URA3, ampR, PCUP1,
SUP35NM-yTagRFP-T
This study




For each plasmid, the following characteristics are indicated: yeast selective marker, (“-”
— the absence of a yeast selective marker), bacterial selective marker, promoter of the
inserted gene, gene of interest. All yeast plasmids in the table are centromeric.
plated on SC-Leu or SC-Ura medium to identify clones which
contain only wild-type SUP35 allele. After selection, the cells
were tested for suppression of the ade1-14mutation to determine
the presence of [PSI+].
The [PSI+] prion loss and transmission were scored according
to the previously described procedure (Afanasieva et al., 2011)
with minor modifications. The [PSI+] strain (10-7A-D832) was
transformed with a LEU2 plasmid bearing the SUP35 or sup35-
M0. To estimate [PSI+] curing, caused by the presence of mutated
sup35 allele, three transformants for each allele were replica
plated three times on a medium lacking uracil, then resuspended
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in water and plated on 1/4 YEPD medium to obtain single
colonies and to reveal the nonsense suppressor phenotype. Then
these clones were replica plated on media lacking uracil or
leucine. The frequency of prion loss was estimated as a fraction of
Ura+Leu– [PSI+] colonies. To determine the efficiency of [PSI+]
transmission from Sup35 to Sup35-M0, 50 transformants for
each combination of SUP35 and sup35-M0 alleles were replica
plated three times on medium lacking leucine containing uracil
to enable the cells to lose plasmid containing wild-type SUP35.
To estimate the efficiency of [PSI+] transmission, the fraction of
Ade+ colonies was scored amongst Ura–Leu+ isolates.
2.4. [PSI+] Induction
Plasmids bearing SUP35NM-GFP or GFP under control of CUP1
promoter were used for the prion induction. Strains [psi–][PIN+]
with corresponding plasmids were grown in selective media at
30◦C to logarithmic phase. For the induction of CUP1 promoter,
CuSO4 was added into the media to the final concentration of
100 µM for the 7A-D832 strain or 50 µM for 12-D1682. Before
induction and after 24 h, the aliquots of cultures were plated
on 1/4 YEPD to count the number of white clones and evaluate
the frequency of their appearance. To compare the amounts of
Sup35NM for different constructions, other aliquots were taken
at the same time points. Cell lysates were obtained with alkaline
lysis (Zhang et al., 2011) and subsequently analyzed with SDS-
PAGE (Sambrook and Fritsch, 1989). The same cells were used
for fluorescence microscopy.
2.5. Decoration of Sup35 Aggregates
in vivo
Two combinations of isogenic strains were used in this
experiment: P-74-D694 and 74-D694, or 10-7A-D832 and 7A-
D832. The first pair (P-74-D694 and 74-D694) was transformed
with plasmids for production of Sup35NM fused with different
fluorescent proteins (Sup35NM-TagRFP-T and Sup35NM-GFP
with substitutions) and corresponding control constructs
(TagRFP-T and GFP). For the TagRFP-T production, cells
with plasmid pIM35 were grown overnight in the liquid
media lacking methionine. For overproduction of the other
constructs with fluorescent proteins, CuSO4 was added to a final
concentration of 50 µM. The second pair of strains (10-7A-D832
and 7A-D832) was transformed with plasmids for production of
Sup35NM-GFP, Sup35NM-M0-GFP or GFP. Overproduction
of these proteins was induced by addition of CuSO4 to a final
concentration of 100µM. In all cases, the induction time was 4 h.
2.6. Propagon Counts
The transformants of 10-7A-D832 with pRS316CUP-NM-GFP
and pRS316CUP-NM-M0-GFP were used for the propagon
counts. The cells were grown in liquid SC-Ura medium with
additional adenine to the early logarithmic phase (OD600 = 0.2).
Then CuSO4 was added to a final concentration of 25 µM.
Cells were plated on YEPD supplemented with 3 mM GuHCl
to obtain single colonies before the addition of CuSO4 and after
one cell culture division (estimated by OD600). The number of
propagons in cells was determined using a previously described
colony-based method (Cox et al., 2003).
2.7. Fluorescence Microscopy
Cells were gently pelleted (2000-3000 rpm) and resuspended
in 50% glycerol. Fluorescence was analyzed using a Zeiss
AxioScope.A1 wide-field fluorescence microscope. Images were
taken with a QIClick-F-CLR-12 (QImaging) camera using
QCAPTURE PRO 7 software.
2.8. Protein Analysis
The amount of Sup35 in different strains was quantified
using Western Blotting with rabbit polyclonal anti-Sup35
antibodies (Chabelskaya et al., 2004). Monoclonal anti-tubulin
antibodies (T6074, Sigma) were used for tubulin detection.
Densitometry measurements were performed in ImageJ software
(Schneider et al., 2012). SDS-PAGE with additional boiling
(Kushnirov et al., 2006) was performed to detect Sup35NM-
GFP and Sup35 in the aggregated and soluble fractions. For
the analysis of Sup35 amyloid aggregates, SDD-AGE was used
(Kryndushkin et al., 2003).
2.9. Protein Purification From Escherichia
coli and Fibril Preparation
For Sup35NM purification, pET-20b-SUP35NM-His6 (Allen
et al., 2005) plasmid or its derivative for Sup35NM-M0
overproduction were used. For protein purification, E. coli
strain BL21(DE3) was used (Studier and Moffattf, 1986).
Overproduction of recombinant proteins was carried out
in 2TYa media with 1 mM IPTG. Cultures were grown
at 37◦C for 6 h. Proteins were purified in denaturing
conditions (in the presence of 8 M urea) according to
previously published protocols (Glover et al., 1997; Serio
et al., 1999). The purification was performed with a two-step
procedure with Ni-NTA agarose (Invitrogen) and Q-sepharose
(GE Healthcare) columns. Proteins were concentrated with a
centrifuge concentrator with molecular weight cutoff of 30
kDa (Millipore).
The obtained Sup35NMproteins were diluted at least 100-fold
into fibril assembly buffer (5 mM potassium phosphate pH 7.5,
150 mM NaCl) to a final protein concentration of 0.5 mg/ml.
In these conditions, Sup35NM spontaneously forms aggregates.
Samples were incubated at 26◦C with slow overhead rotation
(rotator Bio RS-24, Biosan). Tomonitor amyloid fibril formation,
aliquots were removed every 12 h up to 24 h of incubation.
The rate of aggregated protein was estimated by SDS-PAGE with
boiled and unboiled samples.
2.10. TEM and AFM
For fibrils visualization, Jeol JEM-2100 transmission electron
microscope and Bruker Nanoscope V atomic force microscope
were used. The negative staining with a 1% aqueous solution
of uranyl acetate was used for TEM measurements. Samples
were prepared by applying 5 µl of the Sup35NM fibril solution
with concentration 0.5 mg/ml on a substrate, followed by
washing with distilled water and drying. The fibrils were
immobilized on freshly-cleaved mica surface for AFM analysis
and formvar coated copper grids for TEM measurements
(Sokolov et al., 2018).
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2.11. Statistical Analysis
To compare the protein amounts the Mann-Whitney U-test
was used (Mann and Whitney, 1947). The Fisher’s exact test
(Fisher, 1935) was used to compare the proportion of cells with a
particular phenotype. All statistical tests were performed in R (R
Core Team, 2018).
3. RESULTS
3.1. Design of a New sup35 Mutation
In the previous work, we constructed five mutant sup35 alleles,
each of them leading to substitutions of two consecutive polar
residues to charged ones (lysines) in the middle of one of
the oligopeptide repeats (OR1 - OR5). Such mutations are
incompatible with Sup35p aggregates with superpleated β-
structure spanning the ORs with the respective mutations.
These mutations were named sup35KK, and each was designated
according to the number of ORs (from sup35-M1 to sup35-
M5) (Bondarev et al., 2013). We introduced mutations in
all previously known ORs of Sup35 (Kushnirov et al., 1988).
However, using T-REKS program, we identified additional repeat
upstream of the known ORs (28–40 aa) (Bondarev et al., 2013).
To complete the set of sup35KK alleles, we substituted two
residues in the middle of newly identified OR0 (Q33K/A34K)
to lysines and designated this mutation sup35-M0. The potential
effect of this mutation on the Sup35 aggregation was evaluated
with ArchCandy program (Ahmed et al., 2015). Previously
it was shown that this tool accurately predicts the impact
of amino acid substitutions on aggregation properties of a
protein (Ahmed et al., 2015; Bondarev et al., 2015; Roche
et al., 2017). According to the analysis, sup35-M0 mutation
could significantly decrease the amyloidogenic potential of Sup35
and have the highest effect on this parameter compared to
known PNM2 mutation (Doel et al., 1994) and other sup35KK,
which were shown to eliminate the [PSI+] prion (Figure 1)
(Bondarev et al., 2013).
3.2. The sup35-M0 Mutation Efficiently
Eliminates the [PSI+] Prion
To analyze the effect of the mutation, we used previously
described isogenic [PSI+] and [psi–] strains with SUP35 deletion
compensated by a copy of this gene on a URA3 plasmid
(Bondarev et al., 2013). In this system, we can change the alleles
of SUP35 by plasmid shuffling. The presence of the nonsense
mutation ade1-14 in these strains allows monitoring the prion
propagation by the cell phenotype. As [PSI+] strains are able
to suppress ade1-14 mutation, we test for the prion loss by
detecting the decrease in growth on medium lacking adenine
accompanied by increased accumulation of the red pigment on
1/4 YEPD. To check the effect of sup35-M0, we transformed
isogenic [PSI+] and [psi–] strains with a plasmid bearing sup35-
M0 or SUP35 (control). All independent [PSI+] transformants
bearing the mutant allele demonstrated a significant decrease
in nonsense suppression phenotype on 1/4 YEPD (Figure 2A)
or SC media without adenine (data not shown). The complete
elimination of prion phenotype was observed after loss of the
wild-type SUP35 allele (Figure 2A). Yeast cells did not restore
nonsense suppressor phenotype after replacement of a mutant
allele by the wild-type (Figure 2A) suggesting that sup35-M0
mutation leads to the [PSI+] prion loss.
Elimination of the prion should be accompanied by the
elimination of Sup35 aggregates from the cells. We checked for
the disappearance of aggregates in the transformants, which lost
the wild-type SUP35, with SDD-AGE (Kryndushkin et al., 2003)
and did not find Sup35 aggregates in cells bearing only sup35-
M0 (Figure 2B). This fact confirmed our assumption that the
mutation eliminates the prion. We also compared the relative
amount of the Sup35 protein for strains with the wild-type and
FIGURE 1 | Substitutions Q33K/A34K within N-domain of Sup35 decrease the amyloidogenic potential of the protein. The ArchCandy program (Ahmed et al., 2015)
was used to predict amyloidogenic properties. Cumulative scores (sum of β-arch scores counted for each amino acid residue) are presented on the plot. WT —
wild-type protein; G58D, Q33K/A34K, Y46K/Q47K, and Q61K/Q62K substitutions that correspond to mutations PNM2, sup35-M0, -M1, and -M2, respectively.
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FIGURE 2 | sup35-M0 efficiently and irreversibly eliminates [PSI+] prion. (A) The phenotype of strains with different combinations of SUP35 and sup35-M0 alleles in
[PSI+] and [psi–] strains on 1/4 YEPD is shown (images were taken after 4 days of incubation). Transformants bearing two plasmids with two wild-type alleles or
combination of sup35-M0 and SUP35 are presented on the panel “WT/mut” (at least 16 transformants were analyzed). The phenotype of cells after the plasmid loss is
shown on panel “mut”. Finally, sup35-M0 (or SUP35 as a control) were replaced with SUP35 by the reverse plasmid shuffling, phenotype of obtained strains is
presented on panel “WT after mut.” (B) The sup35-M0 allele leads to the elimination of Sup35 aggregates according to SDD-AGE results. Antibodies against Sup35
were used for Western Blotting. (C) Result of Western Blot hybridization after SDS-PAGE analysis of protein lysates from the [psi–] strain with mutant or wild-type allele
of SUP35 with anti-Sup35 and anti-Tub1 antibodies. (D) The densitometry analysis of Sup35 protein level (ten replicates) revealed no difference in Sup35 protein level
in strains with sup35-M0 compared to SUP35. (E) [PSI+] transmission from the wild-type to the indicated sup35 allele. Fraction of cells that retained the prion after
loss of the wild-type allele is shown on graph. (F) [PSI+] loss induced by transient expression of the sup35KK alleles and PNM2 mutation. Fraction of cells that have
lost the prion after the loss of sup35KK allele is shown. **p-value < 0.01 and ***p-value < 0.001 according to Fisher’s exact test.
the mutant SUP35 allele and found no difference (Figures 2C,D),
suggesting that the prion loss was not caused by a decreased
amount of Sup35.
To compare the effects of the new mutation on the prion
replication, we estimated the prion loss and transmission in
the presence of sup35-M0 allele according to special protocols
for each parameter [(Afanasieva et al., 2011), see Materials and
Methods section for details]. We did not observe cases of prion
transmission to the sup35-M0 allele (Figure 2E). At the same
time, the rate of [PSI+] loss was 97.12 ± 0.55% that significantly
exceeds the same parameter for other sup35KK mutations with
a maximum value of ∼40% in case of substitutions within the
secondOR (Figure 2F) (Bondarev et al., 2013). Based on this data
we concluded that new mutation very efficiently eliminates the
[PSI+] prion.
3.3. The Sup35NM-M0 Protein Forms
Infectious Amyloid Aggregates
The highly efficient loss of the prion caused by sup35-M0
suggested that Sup35 with amino acid changes Q33K/A34K
might be unable to form aggregates and induce [PSI+]
formation. To check this hypothesis, we constructed plasmids
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for purification of the Sup35NM-M0 protein from E. coli cells.
We chose only the N-terminal part of the protein because
it is sufficient for aggregation (Glover et al., 1997). Wild-
type Sup35NM protein was used as a control. After 24 h of
incubation in nondenaturing conditions, both proteins formed
SDS-resistant aggregates, detected by comparing the amount
of the proteins in boiled and unboiled samples analyzed with
SDS-PAGE (Figure 3A). Using atomic force microscopy (AFM)
and transmission electron microscopy (TEM) we investigated
the morphology of Sup35NM and Sup35-M0 aggregates and
found no detectable difference between them (Figure 3B). To test
infectious properties of the obtained fibrils, we used the protein
FIGURE 3 | Sup35NM-M0 forms infectious amyloid aggregates. (A) Result of
Coomassie staining of the gel after SDS-PAGE analysis of Sup35 fibrils formed
in vitro. Sup35-M0 forms SDS-resistant aggregates similar to wild-type Sup35.
(B) AFM and TEM images of fibrils formed by Sup35NM or Sup35NM-M0.
(C) Phenotype of [psi–][pin–] strain (2-OT56) transformed with fibrillar or
monomeric proteins on 1/4 YEPD (16 independent transformants are shown
for each case, images were taken after 5 days of incubation). The appearance
of [PSI+] phenotype (white color) after protein transformation suggested
infectious properties of the aggregates.
transformation technique (Tanaka and Weissman, 2006) and
demonstrated that aggregates of both proteins were infectious
and led to [PSI+] appearance (Figure 3C). In all cases, the
observed nonsense suppressor phenotype was prion-mediated
because it was lost after cell growth on the media with GuHCl
(data not shown), which is known to cause the loss of [PSI+]
(Tuite et al., 1981). At the same time, cells transformed with
monomeric protein did not acquire prion phenotype. Thus,
charged residues withinOR0 in Sup35 do not significantly change
its ability to form infectious aggregates in vitro.
3.4. The sup35-M0 Allele Can Induce and
Propagate the [PSI+] Prion but With Low
Efficiency
Next, we analyzed the effect of sup35-M0 allele on the
prion induction in vivo. The presence of another prion
[PIN+] is required for [PSI+] de novo formation in yeast
cells (Derkatch et al., 1997). For this experiment [psi–][PIN+]
strains (derivatives of 7A-D832 or 12-D1682 bearing SUP35 or
sup35-M0) were transformed with plasmids for Sup35NM-GFP
(positive control), Sup35NM-M0-GFP or GFP (negative control)
overproduction. The presence of sup35-M0 in cells significantly
decreased the frequency of [PSI+] formation in different yeast
strains. Furthermore, the overproduction of Sup35NM-M0-GFP
induced [PSI+] with very low efficiency (Figures 4A,B). This
result allowed us to conclude that investigated substitutions
significantly decrease the aggregation propensity of the protein,
as was predicted by the ArchCandy program (Figure 1). We also
compared patterns of Sup35NM-GFP and Sup35NM-M0-GFP
fluorescence upon their overproduction. In all cases, we found
that Sup35 aggregates formed during [PSI+] induction: rings,
ribbons, or dots (Figure 4C), which are detected on the different
stages of the prion life cycle (Tyedmers, 2012).
The low frequency of the prion induction upon sup35NM-
M0 overexpression may also be explained by the effect of
the mutation on the protein stability. However, the levels of
corresponding proteins upon their overproduction are the same
(Figures 4D,E), which contradicts this hypothesis.
To check that the cells with nonsense suppressor phenotype
and bearing sup35-M0 were [PSI+] we isolated several
corresponding clones of 12-D1682. The suppressor phenotype
of these clones was preserved after several passages (Figure 4F)
and in the absence of the plasmid, used for [PSI+] induction, but
eliminated after the growth on GuHCl containing media (data
not shown). We also found aggregates of Sup35 in all analyzed
strains with prion variants (Figure 4G). These results prove the
ability of sup35-M0 to maintain the [PSI+] prion. Nevertheless, it
should be mentioned that all [PSI+] variants formed in presence
of sup35-M0 had weak suppressor phenotype (Figure 4F).
3.5. The Sup35-M0 Protein Can Incorporate
Into Fibrils of the Wild-Type Protein in vivo
We analyzed the ability of the protein with Q33K/A34K
substitutions to incorporate into pre-existing Sup35 aggregates
in vivo. Transient overproduction of Sup35NM fused with
fluorescent protein leads to the decoration of existing Sup35
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FIGURE 4 | sup35-M0 can induce and propagate [PSI+] prion but with low efficiency. (A) Frequencies of [PSI+] induction in the [psi–][PIN+] 7A-D832 (A) and 12-D1682
(B) cells upon overexpression of SUP35NM-GFP (WT) or sup35NM-M0-GFP (M0) in the presence of wild-type or mutant allele of SUP35. Overproduction of GFP
(Continued)
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FIGURE 4 | hereafter was used as a negative control. All constructions were under control of CUP1 promoter, CuSO4 was used for the 24 h induction. All
experiments were repeated six times. Our results demonstrated that the mutation has a dramatically lower potential to induce [PSI+] prion than SUP35
(***p-value < 0.001 according to Fisher’s exact test). The “Allele” designates allele of full-length SUP35 present in cells. (C) The cells tested on panel A were analyzed
with the fluorescence microscopy (scale bar equals 5 µm). Various types of prion aggregates (dots, rings, and ribbons) were detected in the presence of both alleles
(SUP35 and sup35-M0). (D) Results of Western Blot hybridization after SDS-PAGE analysis of protein lysates of strains used for [PSI+] induction. (E) Densitometry
analysis of the Western Blotting. The level of N-terminal domain of Sup35 fused to GFP was normalized to the full-length Sup35-M0 which is unchanged in cells with
wild-type and mutant sup35 allele according to the results presented on the Figure 2 (**p-value < 0.01 according to Mann-Whitney U-test). (F) The nonsense
suppressor phenotype of several [PSI+] variants induced in presence of SUP35 or sup35-M0 in the 12-D1682 strain. Ten independent isolates are shown for each
case. Cells were grown for 4 days on 1/4 YEPD and 5 days on SC-Ade. (G) The results of SDD-AGE analysis of protein lysates of typical [PSI+] variants induced in the
presence of sup35-M0, antibodies against Sup35 were used for Western Blotting.
aggregates and formation of detectable fluorescent foci in cells
(Osherovich et al., 2004). [PSI+][PIN+] and [psi–][PIN+] yeast
strains (P-74-D694 and 74-D694, respectively) were transformed
with the plasmids for overproduction of Sup35NM fused to
a red fluorescent protein, TagRFP-T, in combination with
either Sup35NM-GFP, or Sup35NM-M0-GFP, and analyzed with
fluorescence microscopy. This experiment showed that the
aggregates of Sup35NM and Sup35NM-M0 decorate [PSI+]
aggregates (Figure 5A). One possible explanation of these results
is that independently formed Sup35-M0 fibrils might co-
localize with the wild-type fibrils, however, colocalization of
the fibrils forming de novo in [psi–] strains seems less likely
than co-aggregation of the wild-type and mutant proteins.
Then we rechecked the ability of Sup35-M0 to embed into
aggregates of the prion variant used in experiments with plasmid
shuffle. The isogenic [PSI+][PIN+] and [psi–][PIN+] strains (10-
7A-D832 and 7A-D832, respectively) were analyzed for the
aggregate formation of Sup35NM-GFP or Sup35NM-M0-GFP.
We detected fluorescent foci for both proteins only in [PSI+]
strain (Figure 5B), which suggested the inclusion of the proteins
into pre-existing aggregates, rather than de novo aggregation
of the overproduced proteins. Then the incorporation of
Sup35NM-M0 into amyloid aggregates was analyzed with
SDS-PAGE with modifications, which allowed to evaluate the
distribution of the protein with substitutions between fractions
of detergent-resistant aggregates and monomers (Figure 5C).
The results clearly demonstrated that Sup35NM-M0 was
converted into amyloid-like conformation in the investigated
[PSI+] strain. Taken together these data demonstrated the
ability of the Sup35-M0 to incorporate into various Sup35
aggregates in vivo.
Incorporation of Sup35-M0 into the existing prion aggregates
may have different effects. Previously we proposed that the
analogous mutation in the second OR (sup35-M2) leads to
formation of non-heritable fold and as a result to the prion
loss (Bondarev et al., 2013). The main mechanism responsible
for the prion transmission is a fragmentation of the prion
aggregates by chaperones (Liebman and Chernoff, 2012). An
impairment of this process should lead to the decrease in number
of prion “seeds,” called propagons, and affects the transmission
of the prion upon cell division. We analyzed the effect of
Sup35NM-M0-GFP production on the propagon number after
one generation and found no significant differences compared to
Sup35NM-GFP (Figure 5D). Thus, we considered that sup35-M0
has negligible effect on the aggregate fragmentation.
Finally, using phenotypic assay, we investigated the influence
of the Sup35NM-M0 incorporation into wild-type Sup35
aggregates on the [PSI+] prion properties. One of the effects
of increased Sup35 aggregation in [PSI+] cells is a reduction in
cell viability as overproduction of Sup35NM in [PSI+] strains
may lead to increased prion-dependent lethality (Derkatch, 1998;
Vishveshwara et al., 2009). We checked whether Sup35NM-M0
retained the toxic properties of the wild-type protein. In contrast
to Sup35NM-GFP, overexpression of Sup35NM-M0-GFP did not
lead to a decrease in cell viability (Figure 5E). Overall, our data
imply that the mutant Sup35 is able to co-aggregate with the
wild-type protein, but their coaggregation may destabilize prion
propagation of the native protein.
3.6. The Effect of sup35-M0 Mutation Is
Variant-Unspecific
The effect of sup35 mutations on [PSI+] usually depends on the
prion variant (Derkatch et al., 1999; King, 2001). We checked
whether the effects of sup35-M0 are variant-specific.We obtained
seven new [PSI+] prion variants in the strain with a single
copy of SUP35 on the plasmid (see Materials and Methods
section for details). These strains had different strengths of the
nonsense suppressor phenotype on medium lacking adenine,
and differed in size of Sup35 aggregates (Figures 6A,B). The
replacement of SUP35 by sup35-M0 in these strains led to the
loss of nonsense suppressor phenotype (Figure 6C) and Sup35
aggregates (verified for two investigated strains with SDD-AGE,
data not shown). This allowed us to conclude that the sup35-M0
allele eliminates [PSI+] independently of the prion variant.
4. DISCUSSION
The N-terminal domain of Sup35 is traditionally subdivided onto
QN-rich (1–39 aa) and oligopeptide repeats regions (40–112
aa) (Kushnirov et al., 1988). The minimal region essential for
[PSI+] propagation was assumed to comprise the first 57 residues,
i.e., all QN region and two first ORs (Osherovich et al., 2004;
Shkundina et al., 2006). In this work, we described the effects
of substitutions (Q33K/A34K) within previously uncharacterized
oligopeptide repeat of Sup35 on the [PSI+] prion propagation.
We designated this new mutation as sup35-M0 and showed that
it is able to eliminate [PSI+]. This fact is in good agreement with
position of the mutation, as well as the fact, that the majority of
known PNM mutations is located within the region which was
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FIGURE 5 | The Sup35-M0 protein can incorporate into fibrils of wild-type protein in vivo. (A) [psi–][PIN+] (74-D694) and [PSI+][PIN+] (P-74-D694) yeast strains were
transformed with the plasmids for overproduction of Sup35NM-yTagRFP-T, in combination with either Sup35NM-GFP or Sup35NM-M0-GFP. We observed that
(Continued)
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FIGURE 5 | the aggregates of Sup35NM and Sup35NM-M0 colocalize in [PSI+], as well as in [psi–] cells (scale bar equals 10 µm). (B) The transformants of
[psi–][PIN+] (7A-D832) and [PSI+][PIN+] (10-7A-D832) with overproduced Sup35NM-GFP (WT), or Sup35NM-M0-GFP (M0) were analyzed with fluorescence
microscopy (scale bar equals 5 µm). We detected foci of both proteins only in [PSI+], but not in [psi–], strain, which indicates inclusion of the proteins into existing
aggregates. (C) The result of SDS-PAGE with boiled gel for strains from the panel B was shown. The “Allele” designates allele of full-length SUP35 present in cells. The
Sup35NM-GFP (WT) and Sup35NM-M0-GFP (M0) proteins can incorporate into the existing prion aggregates upon transient overproduction in [PSI+] strain (both are
detected in a fraction of aggregates). (D) Production of Sup35NM-M0-GFP does not affect the number of propagons. The cells from the panel B were used to
calculate number of propagons before and after mild overproduction of Sup35NM-GFP or Sup35NM-M0-GFP; 25 µM CuSO4 was used for the induction. (E) Cells
with overproduction of Sup35NM-TagRFP-T together with Sup35-NM-M0-GFP or Sup35NM-GFP were analyzed for prion toxicity. Cells were plated in 10-fold serial
dilutions and grown for 2 days on SC-LeuUra + Cu2+ or YEPD and 4 days on SC-UraLeu. TagRFP-T production was used as a control; vector — pRS315.
shown to be important for [PSI+] maintenance (DePace et al.,
1998; King, 2001).
The sup35KK mutations, as it was shown previously, may
have different effects on [PSI+] propagation (Bondarev et al.,
2013). Taken together with current results, we can conclude
that proteins with corresponding substitutions within OR0–
OR2 eliminate the prion, but can incorporate into pre-existing
prion aggregates, induce [PSI+] appearance and form amyloid
aggregates in vitro (Bondarev et al., 2013 and paper in
prep). Despite these common features only sup35-M2 and the
sup35-M0 eliminate the prion even in presence of the wild-
type allele (Figure 2F). This allows us to speculate that the
role of first OR in the prion propagation is different from
OR0 or OR2.
The hallmark of sup35-M0 is the higher efficiency of [PSI+]
elimination (97.12 ± 0.55%, Figure 2F) compared to the other
previously characterized PNM mutations. For example, the
prion loss in the presence of PNM2 or sup35-M2 mutations
reachs 20 and 40%, respectively (Bondarev et al., 2013). The
shuffle of SUP35 from S. cerevisiae to the homologs from
other yeast species (S. paradoxus, S. bayanus, S. mikatae,
S. kudriavzevii) may also lead to the [PSI+] elimination
but with lower efficiency than sup35-M0 (Afanasieva et al.,
2011). Furthermore, the prion elimination by the sup35-M0
mutation can destabilize different [PSI+] variants (Figure 6C),
while the effects of all previously described PNM mutations
were variant-specific (Derkatch et al., 1999; King, 2001).
Another specific feature of sup35-M0 is a very low ability to
induce and propagate the prion. Our results suggest that this
mutation can maintain only limited number of weak prion
variants (Figure 4F).
The strong effect of sup35-M0 was not linked to the stability
of the protein as the relative amounts of wild-type and mutant
proteins did not differ (Figures 2C,D). Also, the elimination
of the prion in the presence of sup35-M0 could not be
explained by the complete inability of the protein to propagate
[PSI+]. Sup35NM-M0 can form infectious aggregates in vitro
(Figure 3C), overproduction of Sup35NM-M0-GFP leads to the
prion induction in vivo, and, finally, sup35-M0 can maintain
the prion, though, with low efficiency (Figures 4A,B). The
low prion induction rate upon overproduction of Sup35NM-
M0-GFP and in the presence of sup35-M0 may be explained
by the reduced ability of the soluble protein to aggregate
with itself, as was demonstrated for Sup35-M1 and Sup35-M2
(Khan et al., 2018).
It is noteworthy that our experimental results once again
illustrate the accuracy of ArchCandy prediction (Ahmed et al.,
2015; Bondarev et al., 2015; Roche et al., 2017). We found
that sup35-M0 significantly decreases the frequency of the
prion induction de novo and has lower prionogenic potential
in vivo (Figure 4A). These data are in a good agreement
with the bioinformatics predictions of ArchCandy, according to
which lysines in 33–34 aa positions significantly decrease the
amyloidogenic potential of Sup35 protein (Figure 1).
Prion loss caused by a certain SUP35 allele may occur due to
different mechanisms. In case of the interspecies barrier, three
mechanisms were proposed: the inability of the heterologous
protein to incorporate into prion aggregates, the block of
aggregation by the protein and formation of the non-heritable
fold of aggregates (Afanasieva et al., 2011). Detailed investigation
of [PSI+] elimination caused by PNM2 revealed two potential
processes that may explain nonheritable properties of aggregates:
increased fragmentation leading to solubilization of aggregates
and impairment of prion transmission to the daughter cell
(DiSalvo et al., 2011; Verges et al., 2011; Pei et al., 2017).
We found that Sup35NM-M0 can incorporate into pre-existing
Sup35 aggregates in vivo (Figures 5B,C), but this does not
affect the number of propagons (Figure 5D) and thus the
fragmentation of aggregates. It seems that both mechanisms
could not explain the effect of sup35-M0. We suppose that the
prion loss caused by sup35-M0 is rather linked with the decreased
aggregation propensity of the protein, followed by solubilization
of aggregates by cellular chaperones. This hypothesis is in good
agreement with very low [PSI+] induction rate in the presence
of sup35-M0 (Figure 4A) and prediction of the ArchCandy
(Figure 1). However, this disagrees with the high efficiency of
co-aggregation of Sup35NM-M0 with Sup35 (Figure 5), but we
suggest that differences in aggregation rate in this experiment
may be hidden due to the overproduction of the protein.
In summary, here we described a new mutation in
SUP35, which can efficiently eliminate [PSI+] factor in a
variant-independent manner. The sup35-M0 possess very low
amyloidogenic potential and can protect cells from the
spontaneous appearance of the prion. We suggest that the
investigated mutation may be widely used for fast and non-
specific elimination of the [PSI+] prion or for design of
yeast strains which almost never undergo transition to the
[PSI+] state. Moreover, our discovery may serve as a proof
of concept for the design of a prion-eliminating mutations
using specific bioinformatic tools. In mammals at least two
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FIGURE 6 | The sup35-M0 mutation destabilizes different [PSI+] variants. (A) The suppressor phenotype of the obtained [PSI+] variants (designated by numbers 1-7).
[PSI+] designates the 10-7A-D832 strain. Cells were plated in 10-fold serial dilutions and grown for 3 days on YEPD and 5 days on SC-Ade. (B) The comparison of
Sup35 aggregate size in strains from the panel A. [psi–] is the 12-D1682 strain. (C) The suppressor phenotype of the same strains after the replacement of SUP35 by
sup35-M0. Cells were grown for 3 days on YEPD or 1/4 YEPD and 7 days on SC-Ade.
analogous mutations, eliminating the PrP prion in presence
of the wild type allele, were described. Both of them lead to
substitutions of polar residue to the charged one (Q167R or
Q218K) (Zulianello et al., 2000; Perrier et al., 2002), and it was
shown that the protein with Q218K substitution decreases
formation of PrP amyloid aggregates in vitro (Lee et al., 2007).
Thus, our study supports the design of analogous mutations
that could block propagation of mammalian prion and amyloid
proteins and thus may be useful for amyloidosis therapy.
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